Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCB-204
- Development stage
- Preclinical
- Lead developer
- Dewcell Biotherapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
DCB-204 is an engineered artificial platelet (en-aPLT) therapy developed by Dewcell Biotherapeutics using a proprietary induced pluripotent stem cell (iPSC)-derived platform. Unlike conventional donor-derived platelets, DCB-204 consists of platelets that have been genetically or chemically engineered to enhance their therapeutic functionality, specifically for the treatment of inflammatory conditions. The product is primarily being developed for Acute Respiratory Distress Syndrome (ARDS), leveraging the innate ability of platelets to home to sites of vascular injury and inflammation. By concentrating therapeutic activity within the pulmonary microvasculature, DCB-204 aims to modulate the immune response and reduce tissue damage. This approach provides a standardized, off-the-shelf cell therapy that circumvents the supply limitations and safety risks associated with traditional blood-derived platelet transfusions.
- Other names
- en-aPLT (DCB-204)
Beyond the preview
Go deeper on DCB-204.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCB-204.